EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be effective and safe in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). The Everolimus For Fast Expanded aCcess in TSC SEGA (EFFECTS) study was d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fogarasi, Andras, De Waele, Liesbeth, Bartalini, Gabriella, Jozwiak, Sergiusz, Laforgia, Nicola, Verhelst, Helene, Petrak, Borivoj, Pedespan, Jean-Michel, Witt, Olaf, Castellana, Ramon, Crippa, Stefania, Gislimberti, Gabriella, Gyorsok, Zsuzsanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976509/
https://www.ncbi.nlm.nih.gov/pubmed/27502586
http://dx.doi.org/10.1186/s12883-016-0658-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976509/
https://www.ncbi.nlm.nih.gov/pubmed/27502586
http://dx.doi.org/10.1186/s12883-016-0658-4

Ejemplares similares